Skip to content

TG Therapeutics TGTX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$19.78M+291%$23.04M-1.3%$390.9M+9,975%$28.19M+310%$5.06M+147%
$32K+300%$21K+133%$17K+54.5%$13K-31.6%$8K-72.4%
$19.95M+33.2%$15.65M+31.0%$17.69M+50.2%$16.36M+72.6%$14.97M+60.3%
-$17.89M+37.7%-$23.15M-89.7%-$28.72M-250%
$51K+104%$67K+219%$80K+233%$42K$25K
-$9.86M+23.7%$46.36M+597%-$3.99M-$12.93M-39.8%
$99.99M+1,533%$0-100%$78.24M+3,541%$6.88M$6.12M
$747.66M$0$0
$390.83M+6,505%$0-$78.24M-158%-$6.44M-4,873%-$6.1M-61,120%
$363.07M+860%$0-$55.03M-149%-$3M-$47.75M-174%
-$17.95M+37.6%-$23.23M-90.0%-$28.74M-250%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does TG Therapeutics generate?
TG Therapeutics (TGTX) generated -$95.4M in operating cash flow over the trailing twelve months.
What is TG Therapeutics's free cash flow?
After $240.0K of capital expenditures, TG Therapeutics's free cash flow was -$95.6M over the trailing twelve months, down 66.2% year over year.
Where does TG Therapeutics's cash flow data come from?
Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.